Publications by authors named "K Naqvi"
Outcomes for patients with myeloid blast phase chronic myeloid leukemia (CML-MBP) are dismal, and no preferred chemotherapy regimen has been identified. Recent studies have suggested a higher response rate with administration of timed-sequenced regimens (TSR) (purine analog, high-dose cytarabine, anthracycline) in high-risk acute myeloid leukemia patients. We retrospectively evaluated outcomes of newly diagnosed CML-MBP patients consecutively treated at our institution with a TSR or standard-dose cytarabine and an anthracycline ("7 + 3") combined with a tyrosine-kinase inhibitor (TKI) between 2011 and 2023.
View Article and Find Full Text PDFArticle Synopsis
- Regulatory T cells (T) help maintain immune balance, but their dysfunction can cause diseases like autoimmunity and rejection of transplanted organs, spurring interest in T cell therapies.
- The study introduces a new type of CAR-T cell that specifically targets OX40 ligand (OX40L), controlled by a synthetic promoter to enhance effectiveness and stability in treating these conditions.
- The engineered OX40L-CAR-T cells showed improved activation, suppressing unwanted immune responses more effectively than standard T cells, and demonstrated potential for controlling both graft-versus-host disease and other autoimmune disorders.
Study Objectives: Examine sleep patterns in children with sleep-disordered breathing (SDB) who habitually bedshare.
Methods: We evaluated associations of bedsharing with parent-reported (n=457) and actigraphy-based (n=258) sleep patterns in a diverse child sample (mean age 6.6±2.
Malignancies are reliant on glutamine as an energy source and a facilitator of aberrant DNA methylation. We demonstrate preclinical synergy of telaglenastat (CB-839), a selective glutaminase inhibitor, combined with azacytidine (AZA), followed by a single-arm, open-label, phase 1b/2 study in persons with advanced myelodysplastic syndrome (MDS). The dual primary endpoints evaluated clinical activity, safety and tolerability; secondary endpoints evaluated pharmacokinetics, pharmacodynamics, overall survival, event-free survival and duration of response.
View Article and Find Full Text PDFArticle Synopsis
- The study focuses on improving human immune system (HIS) mouse models for HIV research, using a method to enhance lymph node and circulating T cell levels through the injection of a specific human ligand (rFLT-3 L).* -
- The treatment with the Caspase-1/4 inhibitor VX-765 showed promise in reducing CD4 T cell loss and lowering viral load in key lymphoid tissues, coupled with evidence of decreased viral RNA levels.* -
- These findings suggest that manipulating immune system characteristics in HIS mice can aid in understanding HIV pathology and developing host-directed therapies, although more work is needed to optimize the model further.*